PL374878A1 - Zastosowanie inhibitorów CETP i ewentualnie inhibitorów reduktazy HMG CoA i/lub środków przeciw nadciśnieniu - Google Patents

Zastosowanie inhibitorów CETP i ewentualnie inhibitorów reduktazy HMG CoA i/lub środków przeciw nadciśnieniu

Info

Publication number: PL374878A1
Authority: PL; Poland
Prior art keywords: inhibitors; reductable; antihypertensive agents; hmg coa; cetp
Prior art date: 2002-07-02

Application number

PL03374878A

Other languages

English (en)

Inventor

Tu Trung Nguyen

Charles Lester Shear

James Harold Revkin

Roger Benjamin Ruggeri

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-02

Filing date

2003-06-18

Publication date

2005-11-14

2003-06-18 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-11-14 Publication of PL374878A1 publication Critical patent/PL374878A1/pl

Links

229940030600 antihypertensive agent Drugs 0.000 title 1
239000002220 antihypertensive agent Substances 0.000 title 1
239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Immunology (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Reproductive Health (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)

PL03374878A 2002-07-02 2003-06-18 Zastosowanie inhibitorów CETP i ewentualnie inhibitorów reduktazy HMG CoA i/lub środków przeciw nadciśnieniu PL374878A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US39339502P	2002-07-02	2002-07-02

Publications (1)

Publication Number	Publication Date
PL374878A1 true PL374878A1 (pl)	2005-11-14

Family

ID=30115572

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03374878A PL374878A1 (pl)	2002-07-02	2003-06-18	Zastosowanie inhibitorów CETP i ewentualnie inhibitorów reduktazy HMG CoA i/lub środków przeciw nadciśnieniu

Country Status (23)

Country	Link
US (1)	US20040053842A1 (pl)
EP (1)	EP1519754A1 (pl)
JP (1)	JP2005532388A (pl)
KR (1)	KR20050025578A (pl)
CN (1)	CN1665537A (pl)
AP (1)	AP2004003189A0 (pl)
AU (1)	AU2003244921A1 (pl)
BR (1)	BR0312421A (pl)
CA (1)	CA2488736A1 (pl)
EA (1)	EA200401471A1 (pl)
EC (1)	ECSP045520A (pl)
HR (1)	HRP20041238A2 (pl)
IL (1)	IL165328A0 (pl)
IS (1)	IS7570A (pl)
MA (1)	MA27311A1 (pl)
MX (1)	MXPA05000015A (pl)
NO (1)	NO20050497L (pl)
OA (1)	OA12876A (pl)
PL (1)	PL374878A1 (pl)
TN (1)	TNSN04268A1 (pl)
TW (1)	TW200401768A (pl)
WO (1)	WO2004004778A1 (pl)
ZA (1)	ZA200409582B (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
WO2004056359A1 (en) *	2002-12-20	2004-07-08	Pfizer Products Inc.	Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
JP2006513186A (ja) *	2002-12-20	2006-04-20	ファイザー・プロダクツ・インク	Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
MXPA05007485A (es)	2003-01-14	2006-01-30	Arena Pharm Inc	Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
PT1603553E (pt) *	2003-03-17	2012-02-03	Japan Tobacco Inc	Composições farmacêuticas de inibidores de cetp
WO2004082675A1 (en) *	2003-03-17	2004-09-30	Japan Tobacco Inc.	Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
EA009646B1 (ru) *	2003-05-30	2008-02-28	Рэнбакси Лабораториз Лтд.	Замещённые производные пиррола и их применение в качестве ингибиторов hmg-coa
RS20060018A (sr)	2003-07-14	2007-12-31	Arena Pharmaceuticals Inc.,	Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja
CN1889948A (zh) *	2003-12-16	2007-01-03	诺瓦提斯公司	他汀用于治疗代谢综合征的用途
CA2561564A1 (en) *	2004-04-07	2005-10-27	Millennium Pharmaceuticals, Inc.	Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20060063803A1 (en) *	2004-09-23	2006-03-23	Pfizer Inc	4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
WO2007115131A2 (en) *	2006-03-29	2007-10-11	Guilford F Timothy	Liposomal reduced glutathione and 1-arginine, including other ingredient(s)
WO2006054308A2 (en) *	2004-11-22	2006-05-26	Dexcel Pharma Technologies Ltd.	Stable atorvastatin formulations
JP4954085B2 (ja)	2004-12-06	2012-06-13	メディシノバ，インコーポレイテッド	神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
US7700774B2 (en) *	2004-12-20	2010-04-20	Dr. Reddy's Laboratories Ltd.	Heterocyclic compounds and their pharmaceutical compositions
EP1833466A1 (en) *	2004-12-28	2007-09-19	Ranbaxy Laboratories Limited	Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
CA2605214C (en)	2004-12-31	2016-07-12	Reddy Us Therapeutics, Inc.	Benzylamine derivatives as cetp inhibitors
US8604055B2 (en) *	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
MY148521A (en)	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007106111A2 (en) *	2005-07-01	2007-09-20	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising nilvadipine
WO2007005941A2 (en)	2005-07-05	2007-01-11	President And Fellows Of Harvard College	Liver targeted conjugates
JP2009514851A (ja) *	2005-11-08	2009-04-09	ランバクシーラボラトリーズリミテッド	（３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
TW200744583A (en) *	2006-03-14	2007-12-16	Ranbaxy Lab Ltd	Statin stabilizing dosage formulations
WO2007116243A2 (en) *	2006-04-10	2007-10-18	Mintails Limited	Method for treating fibromyalgia and related conditions
BRPI0714361A2 (pt) *	2006-07-14	2013-03-26	Ranbaxy Lab Ltd	polimorfo cristalino, composiÇço farmacÊutica contendo o mesmo, mÉtodo para sua preparaÇço e mÉtodo de tratamento
US20080181876A1 (en) *	2007-01-30	2008-07-31	Johnson Kirk W	Methods for treating acute and subchronic pain
WO2008137012A1 (en) *	2007-05-03	2008-11-13	Avigen, Inc.	Use of a glial attenuator to prevent amplified pain responses caused by glial priming
US20090074740A1 (en) *	2007-05-14	2009-03-19	Noah Berkowitz	Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (RCT)
WO2009021113A1 (en) *	2007-08-09	2009-02-12	Holtzman, Jordan, L.	Methods for enhancing glutahione peroxidase activity
EP2070520A1 (en) *	2007-12-11	2009-06-17	LEK Pharmaceuticals D.D.	Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
EP3323818A1 (en)	2010-09-22	2018-05-23	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2626351A4 (en) *	2010-10-04	2014-03-12	Kowa Co	MEANS FOR INHIBITING THE EXPRESSION OF MRNA INVOLVED IN THE FAT REPLACEMENT
EP2744803A2 (en)	2011-08-18	2014-06-25	Dr. Reddy's Laboratories Ltd.	Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
MX352074B (es)	2011-09-27	2017-11-08	Dr Reddys Laboratories Ltd	Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
CA2959488C (en) *	2014-08-28	2023-06-20	Dezima Pharma B.V.	Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt)	2015-06-22	2023-12-05	Arena Pharmaceuticals, Inc.	Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
EP3490579B1 (en) *	2016-07-27	2025-09-10	Hartis-Pharma SA	Therapeutic combinations to treat red blood cell disorders
MX2019009841A (es)	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CA3102136A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
CN116196314B (zh) *	2023-05-04	2023-08-15	广州市妇女儿童医疗中心	Ri-1或其盐在制备防治胃肠道疾病的药物中的应用
EP4566597A1 (en) *	2023-12-05	2025-06-11	Hospital Clínic de Barcelona	Statins useful in the treatment of splachnic vascular dysfunctions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6144790A (en) *	1997-02-07	2000-11-07	Bledin; Anthony G	Contact fiber optic impact sensor
AP1207A (en) *	1997-08-29	2003-09-20	Pfizer Prod Inc	Combination therapy.
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.
GT199800126A (es) *	1997-08-29	2000-01-29		Terapia de combinacion.
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) *	1998-09-17	2000-10-31	Pfizer Inc.	Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000050A (es) *	1999-05-27	2001-02-02	Pfizer Prod Inc	Sal mutua de amlodipino y atorvastatina
EP1180102B9 (en) *	1999-05-27	2005-03-02	Pfizer Products Inc.	Mutual prodrugs of amlodipine and atorvastatin
US20030092745A1 (en) *	2000-02-25	2003-05-15	Pfizer Inc.	Combination therapy
US20020013334A1 (en) *	2000-06-15	2002-01-31	Robl Jeffrey A.	HMG-CoA reductase inhibitors and method
CZ2003390A3 (en) *	2000-08-15	2004-03-17	Pfizer Products Inc.	Therapeutic combination of a cetp inhibitor and atorvastatin
US6737430B2 (en) *	2000-11-09	2004-05-18	Pfizer, Inc.	Mutual prodrug of amlodipine and atorvastatin
US20030064967A1 (en) *	2001-04-11	2003-04-03	Jayraz Luchoomun	Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof

2003
- 2003-06-10 US US10/459,683 patent/US20040053842A1/en not_active Abandoned
- 2003-06-18 AP AP2004003189A patent/AP2004003189A0/xx unknown
- 2003-06-18 AU AU2003244921A patent/AU2003244921A1/en not_active Abandoned
- 2003-06-18 IL IL16532803A patent/IL165328A0/xx unknown
- 2003-06-18 BR BR0312421-5A patent/BR0312421A/pt not_active IP Right Cessation
- 2003-06-18 WO PCT/IB2003/002792 patent/WO2004004778A1/en not_active Ceased
- 2003-06-18 CN CN038155753A patent/CN1665537A/zh active Pending
- 2003-06-18 MX MXPA05000015A patent/MXPA05000015A/es not_active Application Discontinuation
- 2003-06-18 OA OA1200400342A patent/OA12876A/en unknown
- 2003-06-18 JP JP2004519080A patent/JP2005532388A/ja not_active Withdrawn
- 2003-06-18 EA EA200401471A patent/EA200401471A1/ru unknown
- 2003-06-18 HR HR20041238A patent/HRP20041238A2/xx not_active Application Discontinuation
- 2003-06-18 KR KR1020057000061A patent/KR20050025578A/ko not_active Ceased
- 2003-06-18 PL PL03374878A patent/PL374878A1/pl not_active Application Discontinuation
- 2003-06-18 EP EP03738394A patent/EP1519754A1/en not_active Withdrawn
- 2003-06-18 CA CA002488736A patent/CA2488736A1/en not_active Abandoned
- 2003-07-01 TW TW092117985A patent/TW200401768A/zh unknown
2004
- 2004-11-26 ZA ZA200409582A patent/ZA200409582B/en unknown
- 2004-11-29 IS IS7570A patent/IS7570A/is unknown
- 2004-12-17 MA MA28016A patent/MA27311A1/fr unknown
- 2004-12-30 EC EC2004005520A patent/ECSP045520A/es unknown
- 2004-12-30 TN TNP2004000268A patent/TNSN04268A1/fr unknown
2005
- 2005-01-28 NO NO20050497A patent/NO20050497L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2004004778A1 (en)	2004-01-15
BR0312421A (pt)	2005-04-19
IS7570A (is)	2004-11-29
TW200401768A (en)	2004-02-01
MXPA05000015A (es)	2005-04-08
JP2005532388A (ja)	2005-10-27
US20040053842A1 (en)	2004-03-18
ECSP045520A (es)	2005-03-10
OA12876A (en)	2006-09-15
HRP20041238A2 (en)	2005-06-30
NO20050497L (no)	2005-03-08
CN1665537A (zh)	2005-09-07
ZA200409582B (en)	2006-08-30
AP2004003189A0 (en)	2004-12-31
AU2003244921A1 (en)	2004-01-23
EP1519754A1 (en)	2005-04-06
KR20050025578A (ko)	2005-03-14
IL165328A0 (en)	2006-01-15
MA27311A1 (fr)	2005-05-02
TNSN04268A1 (fr)	2007-03-12
CA2488736A1 (en)	2004-01-15
EA200401471A1 (ru)	2005-06-30

Legal Events

Date	Code	Title	Description
2010-10-29	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL374878A1 (pl)	2005-11-14	Zastosowanie inhibitorów CETP i ewentualnie inhibitorów reduktazy HMG CoA i/lub środków przeciw nadciśnieniu
PL374364A1 (pl)	2005-10-17	Inhibitory CETP w kombinacji ze środkami przeciw nadciśnieniu i ich zastosowania
AU2003303128A8 (en)	2004-08-13	Inhibitors and methods of use thereof
IL161258A0 (en)	2004-09-27	Heterocyclic compounds and methods of use
AU2003217870A8 (en)	2003-09-16	Pini-modulating compounds and methods of use thereof
EP1549614A4 (en)	2008-04-16	VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
PL376575A1 (pl)	2006-01-09	Podstawione związki heterocykliczne oraz sposoby wykorzystania
ZA200500680B (en)	2006-08-30	Quinoline derivatives and their use as mycrobacterial inhibitors
AU2003278832A8 (en)	2004-04-30	Optical biosensors and methods of use thereof
IL173936A0 (en)	2006-07-05	Heterocyclic inhibitors of mek and methods of use thereof
PL375586A1 (pl)	2005-11-28	Podstawione pochodne amidu kwasu antranilowego oraz sposoby wykorzystania
PL369855A1 (pl)	2005-05-02	4-arylochinazoliny i ich zastosowanie jako inhibitorów NHE-3
EP1512396A4 (en)	2008-12-31	HEMMER AGAINST ACTIVATION OF AP-1 AND NFAT
AU2003231048A8 (en)	2003-11-03	Transposon system and methods of use
IL157659A0 (en)	2004-03-28	New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
PL376566A1 (pl)	2006-01-09	Pochodne podstawionych 2-alkiloamino-nikotynamidów oraz sposoby wykorzystania
AU2003259735A8 (en)	2004-02-25	Small-mer compositions and methods of use
ZA200501913B (en)	2005-07-27	New compounds for the inhibition of rotamases and use thereof
AU2003225668A1 (en)	2003-09-16	Pin1-modulating compounds and methods of use thereof
AU2003213673A1 (en)	2003-09-16	Pin1-modulating compounds and methods of use thereof
EP1497270A4 (en)	2006-01-04	AMID COMPOUNDS AND METHOD FOR THEIR USE
AU2003299441A8 (en)	2004-07-14	Nf-hev compositions and methods of use
AU2003232848A8 (en)	2003-12-31	Phenylaminopyrimidines and their use as rho-kinase inhibitors
PL371217A1 (pl)	2005-06-13	Inhibitory integryny alfaVbeta6
PL374581A1 (pl)	2005-10-31	Diaminotiazole przydatne jako selektywne inhibitory CDK4